{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:44:44Z","timestamp":1786985084007,"version":"build-2736575974"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bcp.2025.116794","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T11:51:46Z","timestamp":1738756306000},"page":"116794","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Role of OX\/OXR cascade in insomnia and sleep deprivation link Alzheimer\u2019s disease and Parkinson\u2019s disease: Therapeutic avenue of Dual OXR Antagonist (DORA)"],"prefix":"10.1016","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6980-6761","authenticated-orcid":false,"given":"Siva Prasad","family":"Panda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6147-3516","authenticated-orcid":false,"given":"Suman","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5374-7453","authenticated-orcid":false,"given":"Adarsh","family":"Kesharwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4986-542X","authenticated-orcid":false,"given":"Sanjesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7982-6934","authenticated-orcid":false,"given":"Gana Manjusha","family":"Kondepudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani Kumar","family":"Sanghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra","family":"Thapliyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kundan Kumar","family":"Chaubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Guru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.116794_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102027","article-title":"Alzheimer\u2019s disease and its related dementias in US Native Americans: A major public health concern","volume":"90","author":"Sehar","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.bcp.2025.116794_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102397","article-title":"Effects of sleep deprivation on brain atrophy in individuals with mild cognitive impairment and Alzheimer\u2019s disease","volume":"99","author":"Sehar","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.bcp.2025.116794_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102047","article-title":"Healthy brain aging and delayed dementia in Texas rural elderly","volume":"91","author":"Basu","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.bcp.2025.116794_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102457","article-title":"Mechanisms, consequences and role of interventions for sleep deprivation: Focus on mild cognitive impairment and Alzheimer\u2019s disease in elderly","volume":"100","author":"Mukherjee","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.bcp.2025.116794_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102335","article-title":"Overlooked cases of mild cognitive impairment: Implications to early Alzheimer\u2019s disease","volume":"98","author":"Mian","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.bcp.2025.116794_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102178","article-title":"Alzheimer\u2019s disease and Alzheimer\u2019s disease-related dementias in Hispanics: Identifying influential factors and supporting caregivers","volume":"93","author":"Rawat","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.bcp.2025.116794_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102537","article-title":"Serotonin in depression and Alzheimer\u2019s disease: Focus on SSRI\u2019s beneficial effects","volume":"101","author":"Tahiri","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.bcp.2025.116794_b0040","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000514960","article-title":"Sleep, orexin and cognition","volume":"45","author":"Toor","year":"2021","journal-title":"Front. Neurol. Neurosci."},{"key":"10.1016\/j.bcp.2025.116794_b0045","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12974-020-01960-9","article-title":"The effect of insomnia on development of Alzheimer\u2019s disease","volume":"17","author":"Sadeghmousavi","year":"2020","journal-title":"J. Neuroinflammation."},{"key":"10.1016\/j.bcp.2025.116794_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00709","article-title":"Orexins as novel therapeutic targets in inflammatory and neurodegenerative diseases","volume":"10","author":"Couvineau","year":"2019","journal-title":"Front. Endocrinol. (lausanne)."},{"key":"10.1016\/j.bcp.2025.116794_b0055","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/pr.109.001321","article-title":"Orexin\/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system","volume":"61","author":"Tsujino","year":"2009","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2025.116794_b0060","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2025.116794_b0065","doi-asserted-by":"crossref","first-page":"36072","DOI":"10.3389\/fendo.2013.00018","article-title":"The physiological role of orexin\/hypocretin neurons in the regulation of sleep\/wakefulness and neuroendocrine functions","volume":"4","author":"Inutsuka","year":"2013","journal-title":"Front. Endocrinol. (lausanne)."},{"key":"10.1016\/j.bcp.2025.116794_b0070","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/bies.1058","article-title":"Hypocretin\/orexin, sleep and narcolepsy","volume":"23","author":"Hungs","year":"2001","journal-title":"Bioessays"},{"key":"10.1016\/j.bcp.2025.116794_b0075","article-title":"A review of physiological functions of orexin: From instinctive responses to subjective cognition","volume":"102","author":"Xia","year":"2023","journal-title":"Med. (United States)."},{"key":"10.1016\/j.bcp.2025.116794_b0080","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/bs.irn.2017.06.006","article-title":"Orexin\/hypocretin system: Role in food and drug overconsumption","volume":"136","author":"Barson","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.bcp.2025.116794_b0085","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.931970","article-title":"The Orexin receptors: Structural and anti-tumoral properties","volume":"13","author":"Couvineau","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"10.1016\/j.bcp.2025.116794_b0090","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/157015909787602797","article-title":"Hypocretin\/orexin neuropeptides: participation in the control of sleep-wakefulness cycle and energy homeostasis","volume":"7","author":"Nunez","year":"2009","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.bcp.2025.116794_b0095","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/bph.12415","article-title":"The hypocretins\/orexins: integrators of multiple physiological functions","volume":"171","author":"Li","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.116794_b0100","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.arr.2014.11.001","article-title":"Sleep disorders, obesity, and aging: the role of orexin","volume":"20","author":"Nixon","year":"2015","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.bcp.2025.116794_b0105","doi-asserted-by":"crossref","DOI":"10.1007\/s11906-018-0879-6","article-title":"Orexins, sleep, and blood pressure","volume":"20","author":"Sieminski","year":"2018","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.bcp.2025.116794_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.00691","article-title":"Evolution of orexin neuropeptide system: structure and function","volume":"14","author":"Soya","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bcp.2025.116794_b0115","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1748-1716.2009.02038.x","article-title":"Hypocretin\/orexin in fish physiology with emphasis on zebrafish","volume":"198","author":"Panula","year":"2010","journal-title":"Acta Physiol."},{"key":"10.1016\/j.bcp.2025.116794_b0120","doi-asserted-by":"crossref","unstructured":"C. Alain, N. Pascal, G. Val\u00e9rie, V. Thierry, Orexins\/Hypocretins and Cancer: A Neuropeptide as Emerging Target, Mol. 2021, Vol. 26, Page 4849. 26 (2021) 4849. doi: 10.3390\/MOLECULES26164849.","DOI":"10.3390\/molecules26164849"},{"key":"10.1016\/j.bcp.2025.116794_b0125","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev-pharmtox-010510-100528","article-title":"Orexin receptors: pharmacology and therapeutic opportunities","volume":"51","author":"Scammel","year":"2011","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bcp.2025.116794_b0130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41583-018-0097-x","article-title":"The neurobiological basis of narcolepsy","volume":"20","author":"Mahoney","year":"2019","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bcp.2025.116794_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2020.135480","article-title":"Increased plasma orexin-A concentrations are associated with the non-motor symptoms in Parkinson\u2019s disease patients","volume":"741","author":"Huang","year":"2021","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bcp.2025.116794_b0140","article-title":"Effect of a dual orexin receptor antagonist on Alzheimer\u2019s disease: Sleep disorders and cognition","volume":"9","author":"Zhou","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.bcp.2025.116794_b0145","doi-asserted-by":"crossref","first-page":"172","DOI":"10.62641\/aep.v52i2.1659","article-title":"Orexinergic receptor antagonists as a new therapeutic target to overcome limitations of current pharmacological treatment of insomnia disorder","volume":"52","author":"\u00c1lamo","year":"2024","journal-title":"Actas Espa\u00f1olas Psiquiatr."},{"key":"10.1016\/j.bcp.2025.116794_b0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ana.26641","article-title":"Suvorexant acutely decreases tau phosphorylation and A\u03b2 in the human CNS","volume":"94","author":"Lucey","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bcp.2025.116794_b0155","doi-asserted-by":"crossref","first-page":"18059","DOI":"10.1073\/pnas.2002704117","article-title":"Structure-based development of a subtype-selective orexin 1 receptor antagonist","volume":"117","author":"Hellmann","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2025.116794_b0160","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1021\/acs.jpcb.8b10220","article-title":"Determinants of orexin receptor binding and activation - a molecular dynamics study","volume":"123","author":"Karhu","year":"2019","journal-title":"J. Phys. Chem. B."},{"key":"10.1016\/j.bcp.2025.116794_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2018.00220","article-title":"The orexin\/receptor system: molecular mechanism and therapeutic potential for neurological diseases","volume":"11","author":"Wang","year":"2018","journal-title":"Front. Mol. Neurosci."},{"issue":"12","key":"10.1016\/j.bcp.2025.116794_b0170","first-page":"2021","article-title":"Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation","volume":"121","author":"Hong","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.116794_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.171009","article-title":"Internal and external modulation factors of the orexin system (REVIEW)","volume":"165","author":"Maruyama","year":"2023","journal-title":"Peptides"},{"key":"10.1016\/j.bcp.2025.116794_b0180","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.50279","article-title":"Common activation mechanism of class A GPCRs","volume":"8","author":"Zhou","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.bcp.2025.116794_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00125","article-title":"GPCR signaling regulation: The role of GRKs and arrestins","volume":"10","author":"Gurevich","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2025.116794_b0190","first-page":"408","article-title":"Involvement of TRPC3 channels in calcium oscillations mediated by OX1 orexin receptors","volume":"385","author":"Peltonen","year":"2009","journal-title":"Elsevier."},{"key":"10.1016\/j.bcp.2025.116794_b0195","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1677\/JOE-08-0536","article-title":"Orexin-stimulated MAP kinase cascades are activated through multiple G-protein signalling pathways in human H295R adrenocortical cells: diverse roles for orexins A and B","volume":"202","author":"Ramanjaneya","year":"2009","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.bcp.2025.116794_b0200","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.neuroscience.2004.05.012","article-title":"Orexins\/hypocretins cause sharp wave- and \u03b8-related synaptic plasticity in the hippocampus via glutamatergic, gabaergic, noradrenergic, and cholinergic signaling","volume":"127","author":"Selbach","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2025.116794_b0205","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2019.00362","article-title":"Effects of intranasal orexin-A (hypocretin-1) administration on neuronal activation, neurochemistry, and attention in aged rats","volume":"11","author":"Calva","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.bcp.2025.116794_b0210","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbr.2007.09.019","article-title":"The effect of antagonization of orexin 1 receptors in CA1 and dentate gyrus regions on memory processing in passive avoidance task","volume":"187","author":"Akbari","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bcp.2025.116794_b0215","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.peptides.2006.11.002","article-title":"The selective orexin 1 receptor antagonist SB-334867-A impairs acquisition and consolidation but not retrieval of spatial memory in Morris water maze","volume":"28","author":"Akbari","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.bcp.2025.116794_b0220","doi-asserted-by":"crossref","unstructured":"J.E. Kang, M.M. Lim, R.J. Bateman, J.J. Lee, L.P. Smyth, J.R. Cirrito, N. Fujiki, S. Nishino, D.M. Holtzman, Amyloid-\u03b2 dynamics are regulated by orexin and the sleep-wake cycle, Science (80-.). 326 (2009) 1005\u20131007. doi: 10.1126\/SCIENCE.1180962\/SUPPL_FILE\/KANG.SOM.PDF.","DOI":"10.1126\/science.1180962"},{"key":"10.1016\/j.bcp.2025.116794_b0225","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1084\/jem.2014178812122014c","article-title":"Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer\u2019s disease","volume":"212","author":"Roh","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2025.116794_b0230","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1241224","article-title":"Sleep drives metabolite clearance from the adult brain","volume":"342","author":"Xie","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bcp.2025.116794_b0235","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3233\/JAD-170108","article-title":"Orexin impairs the phagocytosis and degradation of amyloid-\u03b2 fibrils by microglial cells","volume":"58","author":"An","year":"2017","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.bcp.2025.116794_b0240","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.neulet.2012.07.002","article-title":"Orexin A decreases lipid peroxidation and apoptosis in a novel hypothalamic cell model","volume":"524","author":"Butterick","year":"2012","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bcp.2025.116794_b0245","doi-asserted-by":"crossref","unstructured":"J.H. Roh, H. Jiang, M.B. Finn, F.R. Stewart, T.E. Mahan, J.R. Cirrito, A. Heda, B. Joy Snider, M. Li, M. Yanagisawa, L. de Lecea, D.M. Holtzman, Correction to Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer\u2019s disease [The Journal of Experimental Medicine, 211, 13, (2014), 2487-2496], J. Exp. Med. 211 (2014) 2487\u20132496. doi: 10.1084\/jem.20141788.","DOI":"10.1084\/jem.20141788"},{"key":"10.1016\/j.bcp.2025.116794_b0250","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.5665\/sleep.5846","article-title":"Orexin-A is associated with increases in cerebrospinal fluid phosphorylated-tau in cognitively normal elderly subjects","volume":"39","author":"Osorio","year":"2016","journal-title":"Sleep"},{"key":"10.1016\/j.bcp.2025.116794_b0255","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/jamaneurol.2014.2510","article-title":"Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease","volume":"71","author":"Liguori","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.bcp.2025.116794_b0260","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2174\/156720512804142840","article-title":"Association between hypocretin-1 and amyloid-\u03b242 cerebrospinal fluid levels in alzheimer\u2019s disease and healthy controls","volume":"9","author":"Slats","year":"2012","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.bcp.2025.116794_b0265","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.sleep.2014.02.005","article-title":"Increased cerebrospinal fluid levels of nerve cell biomarkers in narcolepsy with cataplexy","volume":"15","author":"Heier","year":"2014","journal-title":"Sleep Med."},{"key":"10.1016\/j.bcp.2025.116794_b0270","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neulet.2013.12.036","article-title":"Hypocretin in cerebrospinal fluid is positively correlated with Tau and pTau","volume":"561","author":"Deuschle","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bcp.2025.116794_b0275","doi-asserted-by":"crossref","first-page":"8353","DOI":"10.3390\/ijerph19148353","article-title":"Physiological role of orexinergic system for health","volume":"19","author":"Villano","year":"2022","journal-title":"Int. J. Environ. Res. Public Health."},{"key":"10.1016\/j.bcp.2025.116794_b0280","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1111\/ejn.13323","article-title":"Orexin-A increases the activity of globus pallidus neurons in both normal and parkinsonian rats","volume":"44","author":"Xue","year":"2016","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bcp.2025.116794_b0285","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0167-0115(01)00351-2","article-title":"Pressor response to microinjection of orexin\/hypocretin into rostral ventrolateral medulla of awake rats","volume":"104","author":"Machado","year":"2002","journal-title":"Regul. Pept."},{"key":"10.1016\/j.bcp.2025.116794_b0290","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/jnc.14568","article-title":"Orexins increase the firing activity of nigral dopaminergic neurons and participate in motor control in rats","volume":"147","author":"Liu","year":"2018","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2025.116794_b0295","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094508","article-title":"Pathophysiological features of nigral dopaminergic neurons in animal models of parkinson\u2019s disease","volume":"23","author":"Guatteo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.116794_b0300","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2018.00835","article-title":"Orexin - A exerts neuroprotective effects via OX1R in Parkinson\u21d4s disease","volume":"12","author":"Liu","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bcp.2025.116794_b0305","doi-asserted-by":"crossref","DOI":"10.1177\/2058738418785739","article-title":"Orexin-A protects SH-SY5Y cells againstH2O2-induced oxidative damage via thePI3K\/MEK1\/2\/ERK1\/2 signaling pathway","volume":"32","author":"Wang","year":"2018","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.bcp.2025.116794_b0310","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neulet.2014.07.014","article-title":"Neuroprotection by Orexin-A via HIF-1\u03b1 induction in a cellular model of Parkinson\u2019s disease","volume":"579","author":"Feng","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bcp.2025.116794_b0315","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1212\/01.WNL.0000078194.53210.48","article-title":"Low levels of ventricular CSF orexin\/hypocretin in advanced PD","volume":"61","author":"Drouot","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2025.116794_b0320","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9060598","article-title":"A guide to the generation of a 6-hydroxydopamine mouse model of Parkinson\u2019s disease for the study of non-motor symptoms","volume":"9","author":"Masini","year":"2021","journal-title":"Biomedicines."},{"key":"10.1016\/j.bcp.2025.116794_b0325","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12264-010-0410-9","article-title":"Progressive changes of orexin system in a rat model of 6-hydroxydopamine-induced Parkinson\u2019s disease","volume":"26","author":"Cui","year":"2010","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.bcp.2025.116794_b0330","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci12111473","article-title":"Narcolepsy\u2014a neuropathological obscure sleep disorder: a narrative review of current literature","volume":"12","author":"Chavda","year":"2022","journal-title":"Brain Sci."},{"key":"10.1016\/j.bcp.2025.116794_b0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279747","article-title":"Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson\u2019s disease: A retrospective study","volume":"17","author":"Ogawa","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2025.116794_b0340","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/01616412.2017.1352185","article-title":"The effect of orexin-A on motor and cognitive functions in a rat model of Parkinson\u2019s disease","volume":"39","author":"Hadadianpour","year":"2017","journal-title":"Neurol. Res."},{"key":"10.1016\/j.bcp.2025.116794_b0345","doi-asserted-by":"crossref","unstructured":"S. Guerreiro, C. Florence, E. Rousseau, S. Hamadat, E.C. Hirsch, P.P. Michel, The sleep-modulating peptide orexin-B protects midbrain dopamine neurons from degeneration, alone or in cooperation with nicotine, ASPETS Guerr. C Florence, E Rousseau, S Hamadat, EC Hirsch, PP MichelMolecular Pharmacol. 2015\u2022ASPET. 87 (2015) 525\u2013532. doi: 10.1124\/mol.114.095703.","DOI":"10.1124\/mol.114.095703"},{"key":"10.1016\/j.bcp.2025.116794_b0350","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.neuint.2013.09.022","article-title":"Protective effect of orexin-A on 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells","volume":"63","author":"Esmaeili-Mahani","year":"2013","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bcp.2025.116794_b0355","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/brain\/awm097","article-title":"Hypocretin (orexin) cell loss in Parkinson\u2019s disease","volume":"130","author":"Thannickal","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.bcp.2025.116794_b0360","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/rej.2016.1836","article-title":"Orexin-A protects human neuroblastoma SH-SY5Y cells against 6-hydroxydopamine-induced neurotoxicity: involvement of PKC and PI3K signaling pathways","volume":"20","author":"Pasban-Aliabadi","year":"2017","journal-title":"Rejuvenation Res."},{"key":"10.1016\/j.bcp.2025.116794_b0365","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1365-2869.2012.01027.x","article-title":"Progressive dopamine and hypocretin deficiencies in Parkinson\u2019s disease: Is there an impact on sleep and wakefulness?","volume":"21","author":"Wienecke","year":"2012","journal-title":"J. Sleep Res."},{"key":"10.1016\/j.bcp.2025.116794_b0370","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.00132","article-title":"Pharmacological characteristics of porcine orexin 2 receptor and mutants","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"10.1016\/j.bcp.2025.116794_b0375","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13902","article-title":"The orexin story and orexin receptor antagonists for the treatment of insomnia","volume":"32","author":"Muehlan","year":"2023","journal-title":"J. Sleep Res."},{"key":"10.1016\/j.bcp.2025.116794_b0380","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1055\/s-0043-1770805","article-title":"Daridorexant, a recently approved dual orexin receptor antagonists (DORA) in Treatment of insomnia","volume":"16","author":"Chakraborty","year":"2023","journal-title":"Sleep Sci."},{"key":"10.1016\/j.bcp.2025.116794_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2018.08.025","article-title":"Therapeutics development for addiction: Orexin-1 receptor antagonists","volume":"1731","author":"Perrey","year":"2020","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2025.116794_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2022.173464","article-title":"Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model","volume":"220","author":"Ishikawa","year":"2022","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bcp.2025.116794_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2023.173690","article-title":"The orexin receptor 2 (OX2R)-selective agonist TAK-994 increases wakefulness without affecting cerebrospinal fluid orexin levels in cynomolgus monkeys","volume":"234","author":"Yamada","year":"2024","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bcp.2025.116794_b0400","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.neuropharm.2004.02.014","article-title":"Pharmacological characterisation of the orexin receptor subtype mediating postsynaptic excitation in the rat dorsal raphe nucleus","volume":"46","author":"Soffin","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2025.116794_b0405","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa2301940","article-title":"Oral orexin receptor 2 agonist in narcolepsy type 1","volume":"389","author":"Dauvilliers","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2025.116794_b0410","article-title":"Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist","author":"Maehara","year":"2020","journal-title":"SDM-878"},{"key":"10.1016\/j.bcp.2025.116794_b0415","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/j.1476-5381.2009.00127.x","article-title":"Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX2 receptor","volume":"156","author":"Malherbe","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.116794_b0420","doi-asserted-by":"crossref","first-page":"179","DOI":"10.5115\/acb.21.202","article-title":"A study on the effect of JNJ-10397049 on proliferation and differentiation of neural precursor cells","volume":"55","author":"Karami","year":"2022","journal-title":"Anat. Cell Biol."},{"key":"10.1016\/j.bcp.2025.116794_b0425","article-title":"The selective orexin-2 antagonist seltorexant (JNJ-42847922\/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder","volume":"9","author":"Recourt","year":"2019","journal-title":"Transl. Psychiatry."},{"key":"10.1016\/j.bcp.2025.116794_b0430","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00213-016-4280-3","article-title":"Effects of dorsal hippocampal orexin-2 receptor antagonism on the acquisition, expression, and extinction of morphine-induced place preference in rats","volume":"233","author":"Sadeghi","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2025.116794_b0435","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/cmdc.201300003","article-title":"Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist","volume":"8","author":"Steiner","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bcp.2025.116794_b0440","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1007\/s00213-017-4673-y","article-title":"Hypocretin receptor 1 blockade produces bimodal modulation of cocaine-associated mesolimbic dopamine signaling","volume":"234","author":"Levy","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2025.116794_b0445","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bjp.0703953","article-title":"SB-334867-A: the first selective orexin-1 receptor antagonist","volume":"132","author":"Smart","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.116794_b0450","first-page":"131","article-title":"Ox1r antagonist SB408124 action and extrahypothalamic CRF in rats after psychotraumatic exposure","volume":"290","author":"Tissen","year":"2019","journal-title":"Georgian Med. News."},{"issue":"36","key":"10.1016\/j.bcp.2025.116794_b0455","article-title":"Differential effects of the dual orexin receptor antagonist almorexant and the GABAA-\u03b11 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat","volume":"364","author":"Steiner","year":"2011","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.bcp.2025.116794_b0460","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","article-title":"Daridorexant: first approval","volume":"82","author":"Markham","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2025.116794_b0465","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyw022","article-title":"A phase II dose-ranging study evaluating the efficacy and safety of the orexin receptor antagonist filorexant (MK-6096) in patients with primary insomnia","volume":"19","author":"Connor","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bcp.2025.116794_b0470","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.5665\/sleep.1996","article-title":"The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia","volume":"35","author":"Bettica","year":"2012","journal-title":"Sleep"},{"key":"10.1016\/j.bcp.2025.116794_b0475","first-page":"1358","article-title":"Lemborexant","volume":"77","author":"Ardeljan","year":"2023","journal-title":"Am. J. Heal. Pharm."},{"key":"10.1016\/j.bcp.2025.116794_b0480","first-page":"2022","article-title":"Suvorexant, a novel dual orexin receptor antagonist, for the management of insomnia","volume":"10","author":"Han","year":"2022","journal-title":"Heal. Psychol. Res."},{"key":"10.1016\/j.bcp.2025.116794_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115489","article-title":"Discovery of ORN0829, a potent dual orexin 1\/2 receptor antagonist for the treatment of insomnia","volume":"28","author":"Futamura","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2025.116794_b0490","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11920-022-01357-w","article-title":"Orexin receptor antagonists and insomnia","volume":"24","author":"Wu","year":"2022","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.bcp.2025.116794_b0495","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s000180300005","article-title":"Orexins and their receptors: structural aspects and role in peripheral tissues","volume":"60","author":"Voisin","year":"2003","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bcp.2025.116794_b0500","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1175372","article-title":"Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis","volume":"14","author":"Xue","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2025.116794_b0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000369101","article-title":"Amyloid-beta: a crucial factor in alzheimer\u2019s disease","volume":"24","author":"Sadigh-Eteghad","year":"2015","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.bcp.2025.116794_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102086","article-title":"Impose of KNDy\/GnRH neural circuit in PCOS, ageing, cancer and Alzheimer\u2019s disease: StAR actions in prevention of neuroendocrine dysfunction","volume":"92","author":"Panda","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.bcp.2025.116794_b0515","doi-asserted-by":"crossref","first-page":"616","DOI":"10.30773\/pi.2020.0136","article-title":"Orexin and alzheimer\u2019s disease: a new perspective","volume":"17","author":"Um","year":"2020","journal-title":"Psychiatry Investig."},{"key":"10.1016\/j.bcp.2025.116794_b0520","doi-asserted-by":"crossref","first-page":"307","DOI":"10.32598\/bcn.9.5.307","article-title":"Tau pathology of alzheimer disease: possible role of sleep deprivation","volume":"9","author":"Ahmadian","year":"2018","journal-title":"Basic Clin. Neurosci."},{"key":"10.1016\/j.bcp.2025.116794_b0525","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2217\/nmt.14.33","article-title":"The sleep\u2013wake cycle and Alzheimer\u2019s disease: what do we know?","volume":"4","author":"Lim","year":"2014","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.bcp.2025.116794_b0530","doi-asserted-by":"crossref","unstructured":"E. Urrestarazu, J.I.-N. and science of sleep, undefined 2016, Clinical management of sleep disturbances in Alzheimer\u2019s disease: current and emerging strategies, Taylor Fr. Urrestarazu, J IriarteNature Sci. Sleep, 2016\u2022Taylor Fr. 8 (2016) 21\u201333. doi: 10.2147\/NSS.S76706.","DOI":"10.2147\/NSS.S76706"},{"key":"10.1016\/j.bcp.2025.116794_b0535","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s12640-021-00411-4","article-title":"Exploring the role of orexinergic neurons in parkinson\u2019s disease","volume":"39","author":"Kumar","year":"2021","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.bcp.2025.116794_b0540","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.713201","article-title":"Orexinergic system in neurodegenerative diseases","volume":"13","author":"Wang","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.bcp.2025.116794_b0545","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13041-019-0514-8","article-title":"Pharmacological and chemogenetic orexin\/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson\u2019s disease","volume":"12","author":"Stanojlovic","year":"2019","journal-title":"Mol. Brain."},{"issue":"26","key":"10.1016\/j.bcp.2025.116794_b0550","article-title":"The amyloid-\u03b2 pathway in alzheimer\u2019s disease","volume":"2610","author":"Hampel","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2025.116794_b0555","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/WAD.0000000000000010","article-title":"Sleep habits in mild cognitive impairment","volume":"28","author":"Hayes","year":"2014","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.bcp.2025.116794_b0560","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41386-019-0478-5","article-title":"Bidirectional relationship between sleep and Alzheimer\u2019s disease: role of amyloid, tau, and other factors","volume":"45","author":"Wang","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2025.116794_b0565","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.biopsych.2017.11.031","article-title":"The emerging relationship between interstitial fluid-cerebrospinal fluid exchange, amyloid \u03b2 and sleep","volume":"83","author":"Boespflug","year":"2018","journal-title":"Biol. Psychiatry."},{"key":"10.1016\/j.bcp.2025.116794_b0570","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.27691","article-title":"Suvorexant for reduction of delirium in older adults after hospitalization: a randomized clinical trial","volume":"7","author":"Hatta","year":"2024","journal-title":"JAMA Netw. Open."},{"key":"10.1016\/j.bcp.2025.116794_b0575","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.5664\/jcsm.7282","article-title":"An update on dual orexin receptor antagonists and their potential role in insomnia therapeutics","volume":"14","author":"Janto","year":"2018","journal-title":"J. Clin. Sleep Med."},{"key":"10.1016\/j.bcp.2025.116794_b0580","doi-asserted-by":"crossref","first-page":"7590","DOI":"10.1021\/jm4007627","article-title":"Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia","volume":"56","author":"Betschart","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.116794_b0585","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2014.00008","article-title":"Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep\/wakefulness states in mice","volume":"8","author":"Etori","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bcp.2025.116794_b0590","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5664\/jcsm.5382","article-title":"Effects of suvorexant, an orexin receptor antagonist, on respiration during sleep in patients with obstructive sleep apnea","volume":"12","author":"Sun","year":"2016","journal-title":"J. Clin. Sleep Med."},{"key":"10.1016\/j.bcp.2025.116794_b0595","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1476-5381.2009.00476.x","article-title":"The impact of GPCR structures on pharmacology and structure-based drug design","volume":"159","author":"Congreve","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.116794_b0600","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nsmb.3183","article-title":"Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors","volume":"23","author":"Yin","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"519","key":"10.1016\/j.bcp.2025.116794_b0605","article-title":"Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant","volume":"5197542","author":"Yin","year":"2014","journal-title":"Nat."},{"key":"10.1016\/j.bcp.2025.116794_b0610","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1021\/acs.jmedchem.9b01787","article-title":"Comparison of orexin 1 and orexin 2 ligand binding modes using X-ray crystallography and computational analysis","volume":"63","author":"Rappas","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.116794_b0615","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1016\/j.bmc.2014.08.034","article-title":"Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists","volume":"22","author":"Yoshida","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2025.116794_b0620","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.5664\/jcsm.6800","article-title":"Lemborexant, A dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a bayesian, adaptive, randomized, double-blind, placebo-controlled study","volume":"13","author":"Murphy","year":"2017","journal-title":"J. Clin. Sleep Med."},{"key":"10.1016\/j.bcp.2025.116794_b0625","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/0333102414544979","article-title":"Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis","volume":"35","author":"Chabi","year":"2015","journal-title":"Cephalalgia"},{"key":"10.1016\/j.bcp.2025.116794_b0630","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.neuropharm.2011.10.003","article-title":"Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia","volume":"62","author":"Winrow","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2025.116794_b0635","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.5665\/sleep.2232","article-title":"The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors","volume":"35","author":"Mang","year":"2012","journal-title":"Sleep"},{"key":"10.1016\/j.bcp.2025.116794_b0640","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1021\/acs.jmedchem.5b00832","article-title":"Orexin receptor antagonists: new therapeutic agents for the treatment of insomnia","volume":"59","author":"Roecker","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.116794_b0645","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1124\/dmd.110.035386","article-title":"Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans","volume":"39","author":"Renzulli","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2025.116794_b0650","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2012.07.007","article-title":"Functional and binding kinetic studies make a distinction between OX1 and OX2 orexin receptor antagonists","volume":"692","author":"Faedo","year":"2012","journal-title":"Eur. J. Pharmacol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225000565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225000565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T08:13:59Z","timestamp":1745828039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225000565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":130,"alternative-id":["S0006295225000565"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116794","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of OX\/OXR cascade in insomnia and sleep deprivation link Alzheimer\u2019s disease and Parkinson\u2019s disease: Therapeutic avenue of Dual OXR Antagonist (DORA)","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116794","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116794"}}